Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K von Bergmann

Showing results (11-20 of 144) with videos related to

Pageof 15
Sort By:
Klinische Wochenschrift|November 15, 1985
Comparison of biliary lipid secretion in non-obese cholesterol gallstone patients with normal, young, male volunteersO Leiss, K von Bergmann
International Journal of Clinical Pharmacology and Therapeutics|February 28, 2003
Clinical trials, industrial sponsoring, and ethics--a never ending story?T Sudhop, K von Bergmann
Zeitschrift Fur Kardiologie|December 16, 2004
Sitosterolemia--a rare disease. Are elevated plant sterols an additional risk factor?T Sudhop, K von Bergmann
Annals of Medicine|June 1, 1997
Phytosterolaemia: diagnosis, characterization and therapeutical approachesD Lütjohann, K von Bergmann
Gut|January 1, 1985
Effect of Rowachol on biliary lipid secretion and serum lipids in normal volunteersO Leiss, K von Bergmann
MMW Fortschritte Der Medizin|November 11, 2003
[Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins]Th Sudhop, K von Bergmann
European Journal of Clinical Investigation|April 1, 1984
Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemiaK von Bergmann, O Leiss
Scandinavian Journal of Gastroenterology|August 1, 1982
Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstonesO Leiss, K von Bergmann
MMW Fortschritte Der Medizin|July 9, 2003
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?]Th Sudhop, K von Bergmann
Therapeutische Umschau. Revue Therapeutique|October 1, 1995
[Pharmacotherapy with endogenous substances]K Von Bergmann, B H Lauterburg
Pageof 15

Showing results (11-20 of 144) with videos related to

Sort By:
Pageof 15
Klinische Wochenschrift|November 15, 1985
Comparison of biliary lipid secretion in non-obese cholesterol gallstone patients with normal, young, male volunteersO Leiss, K von Bergmann
International Journal of Clinical Pharmacology and Therapeutics|February 28, 2003
Clinical trials, industrial sponsoring, and ethics--a never ending story?T Sudhop, K von Bergmann
Zeitschrift Fur Kardiologie|December 16, 2004
Sitosterolemia--a rare disease. Are elevated plant sterols an additional risk factor?T Sudhop, K von Bergmann
Annals of Medicine|June 1, 1997
Phytosterolaemia: diagnosis, characterization and therapeutical approachesD Lütjohann, K von Bergmann
Gut|January 1, 1985
Effect of Rowachol on biliary lipid secretion and serum lipids in normal volunteersO Leiss, K von Bergmann
MMW Fortschritte Der Medizin|November 11, 2003
[Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins]Th Sudhop, K von Bergmann
European Journal of Clinical Investigation|April 1, 1984
Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemiaK von Bergmann, O Leiss
Scandinavian Journal of Gastroenterology|August 1, 1982
Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstonesO Leiss, K von Bergmann
MMW Fortschritte Der Medizin|July 9, 2003
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?]Th Sudhop, K von Bergmann
Therapeutische Umschau. Revue Therapeutique|October 1, 1995
[Pharmacotherapy with endogenous substances]K Von Bergmann, B H Lauterburg
Pageof 15